With the rise of new drugs that can target the amyloid-beta plaques in the brain that are an early sign of Alzheimer’s disease, new ways are needed to determine whether memory loss and thinking problems are due to Alzheimer’s disease or another neurodegenerative disorder.
The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS